IGFBP-6 Antibody (001) [Allophycocyanin]

• Reactivity: Hu
• Applications: ELISA, ELISA
• Clone: 001
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Allophycocyanin

IGFBP-6 Antibody (001) [Allophycocyanin] Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: This antibody was obtained from a rabbit immunized with purified, recombinant Human IGFBP-6 (Uniprot#: P24592; Met1-Gly240).
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: IGFBP6
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Sandwich ELISA Detection
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Alternate Names for IGFBP-6 Antibody (001) [Allophycocyanin]

• IBP6
• IBP-6
• IGF binding protein 6
• IGF-binding protein 6
• IGFBP6
• IGFBP-6
• insulin-like growth factor binding protein 6
• insulin-like growth factor-binding protein 6

Background

Data show that an increase in JNK activation in the presence of NFkappaB inhibition significantly increased the expression of IGFBP6. These studies provide evidence that over expression of IGFBP-6 suppresses human and murine osteoblast differentiation, that IGFBP-6 and LMP-1 physically interact, and supports the conclusion that this interaction may be functionally relevant. IGFBP-6 is the effector of tumor suppressor activity of SEMA3B. Observational study of gene-disease association. (HuGE Navigator) IGFBP-6 is translocated to the nucleus with functional consequences, and different members of the IGFBP family have specific nuclear import mechanisms. Toxic effect of TCDD on osteogenesis through altering IGFBP6 gene expression in osteoblasts is reported. p38 MAPK is involved in IGFBP-6-induced IGF-independent rhabdomyosarcoma cell migration. determination of blood levels in adult patients with severe liver disease before and after orthotopic liver transplantation. Inhibition of human osteoblast marker gene expression by retinoids is mediated in part by insulin-like growth factor binding protein-6. A close correlation exists between residues of the carboxyl-terminal domain of IGFBP6 undergoing conformational change in 15N NMR spectroscopy studies with those that disappeared or broadened upon insulin-like growth factor (IGF-II) binding. C-domain of IGFBP-6 consists of a thyroglobulin type 1 fold comprising an alpha-helix followed by a loop, a three-stranded antiparallel beta-sheet incorporating a second loop, and a disulfide-bonded flexible third loop. The expression of certain IGFBP is significantly altered in renal cell carcinoma. CCI-779 acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo. may function as an antiproliferative molecule suppressing mitogenic effects of insulin-like growth factors on Malassez cells. The IGFBP-6 protein is synthesized as propeptides with a hydrophobic leader sequence, removal of which yields a mature protein composed of 3 recognizable domains of similar size. transgenic human IGFBP-6 mice may be considered a new tool for studies of the involvement of the brain IGF system in metabolism control and obesity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IGFBP6